Helixor M (Liquid Extract From Viscum Album Subsp. Album Var Malus Domestica (1:20), Extraction Solvents: Water)

Helixor M is used in clinical practice primarily as an adjunctive therapy in supportive care, particularly in oncology settings, although it does not have an approved therapeutic indication in most jurisdictions.

• Investigational use as complementary therapy in cancer care.
• Applied in studies evaluating quality‑of‑life outcomes.
• Utilized in protocols exploring immunomodulatory effects of mistletoe extracts.
• Administered under physician supervision as part of individualized treatment plans.

Adverse reactions reported with subcutaneous Viscum album extracts vary in frequency and severity.

Common

• Local redness or swelling at injection site.
• Mild fever or flu‑like symptoms.
• Transient headache.
• Nausea or mild gastrointestinal discomfort.

Serious

• Allergic reactions including urticaria or angioedema.
• Severe hypotension or anaphylactic shock.
• Significant liver enzyme elevation.
• Persistent high fever.

Healthcare providers should consider several precautionary measures before prescribing Helixor M.

• Assess patient for known hypersensitivity to mistletoe or related plants.
• Review medical history for autoimmune disorders.
• Monitor vital signs during initial administrations.
• Evaluate liver function tests periodically.
• Use caution in patients receiving immunosuppressive therapy.
• Avoid use during pregnancy or lactation unless benefits outweigh risks.

Helixor M may interact with other agents, requiring attention to avoid adverse outcomes.

Avoid

• Concurrent use with other immunostimulatory botanicals without medical oversight.
• Combination with anticoagulants that increase bleeding risk.

Use with caution

• Concomitant chemotherapy agents (potential additive immunomodulation).
• Vaccines (possible alteration of immune response).
• Drugs metabolized by hepatic enzymes (monitor liver function).